Mesenchymal stem cells derived from the placenta and its secretions in the treatment of graft versus host disease

Effect of mesenchymal stem cells derived from the placenta and their secretome for the treatment of GVHD: A triple-blinded randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201108049311N7

Enrollment

Registered

2023-09-28

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft versus host disease. Graft-versus-host disease

Interventions

Intervention 1: Intervention group: Recipient of 6 doses secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400

Eligibility

Sex/Gender

All

Age

16 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with acute GVHD with fever and requiring hospitalization

Exclusion criteria

Exclusion criteria: Patients with sepsis

Design outcomes

Primary

Measure	Time frame
Skin rash. Timepoint: At the beginning of the study and 6 weeks after the intervention. Method of measurement: Examination of appearance (shape, color and texture of skin rash), determination of BSA percentage and staging based on it.;Liver involvement. Timepoint: At the beginning of the study and 6 weeks after the intervention. Method of measurement: Measurement of Bilirubin level.;Intestine condition. Timepoint: At the beginning of the study and 6 weeks after the intervention. Method of measurement: Diarrhea volume measurement.	—

Measure

Time frame

Skin rash. Timepoint: At the beginning of the study and 6 weeks after the intervention. Method of measurement: Examination of appearance (shape, color and texture of skin rash), determination of BSA percentage and staging based on it.;Liver involvement. Timepoint: At the beginning of the study and 6 weeks after the intervention. Method of measurement: Measurement of Bilirubin level.;Intestine condition. Timepoint: At the beginning of the study and 6 weeks after the intervention. Method of measurement: Diarrhea volume measurement.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abolfazl Barzegari

Tabriz University of Medical Sciences

barzegari.abolfazl@gmail.com+98 41 3336 7929

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026